Vera Therapeutics announced positive results from its Phase 2b ORIGIN clinical trial for atacicept in patients with IgAN, achieving statistical significance in reducing proteinuria and stabilizing eGFR.
AI Assistant
VERA THERAPEUTICS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.